Who makes other class IC antiarrhythmic drug?

other class IC antiarrhythmic drug is developed by Korea University.

What development phase is other class IC antiarrhythmic drug in?

other class IC antiarrhythmic drug is in Phase 1.

Last reviewed 2026-04-20 · How we verify

other class IC antiarrhythmic drug

Korea University · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	other class IC antiarrhythmic drug
Also known as	flecainide 100mg bid PO or propafenone 225mg tid
Sponsor	Korea University
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

other class IC antiarrhythmic drug CI brief — competitive landscape report
other class IC antiarrhythmic drug updates RSS · CI watch RSS
Korea University portfolio CI